MedTrace Logo

Coenzyme Q10 Supplementation in Children With Idiopathic Dilated Cardiomyopathy

NCT02115581 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2014-04-16

Study results available
· View outcomes & findings →

Summary

This study aims to determine the effect of Coenzyme Q10 supplementation on conventional therapy of children with heart failure due to idiopathic dilated cardiomyopathy.

Conditions

  • Dilated Cardiomyopathy

Interventions

DRUG

Coenzyme Q10

dose of 2 mg/kg/day in 2 or 3 divided doses and increased to the maximum dose of 10 mg/kg/day according to the patient's tolerance

DRUG

Placebo

dose of 2 mg/kg/day in 2 or 3 divided doses and increased to the maximum dose of 10 mg/kg/day according to the patient's tolerance

Sponsors & Collaborators

  • University of Tehran

    lead OTHER

Principal Investigators

  • Reza Shabanian, MD · Children's Medical Center

  • Armen Kocharian, MD · Children's Medical Center

  • Giv Heidari-Bateni, MD/MPH · Children's Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
6 Months
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2008-03-31
Completion
2008-03-31

Countries

  • Iran

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02115581 on ClinicalTrials.gov